Answers from the Lab

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly update. In this episode, Dr. Morice explains his dual leadership role and how engaging in the business of a reference laboratory informs his work within academic medicine.

(00:31):But before we get started, Dr. Pritt, could you provide our listeners with a little bit about you and your background? (01:22):Can you provide a brief overview and intended use of this testing? (03:16):Could you describe what clinical action is enabled by the results of this test? (05:31):Now let's discuss which patients should have this testing and when should it be performed?’ (06:56):Can you now explain, how does this test improve upon previous testing approaches? (08:04):Are there other options on the market? If so, what makes our testing different or unique?

(00:31):Before we get started, Dr. Halling, could you provide us with a little bit about you and your background? (01:11):Would you like to give us a basic summary of this test?(02:43):So in talking about patients, can you tell us which patients should have this testing? And when it is typically performed? (05:01):Do you want to talk about some of the guidelines that were used to shape the genes included in this panel? (05:36):Can you tell us a bit about the alternative test options that are available and how they compare to this large panel? (06:42):So I know most other panels on the market assess for mutations and fusions. Is there a reason why our panel also looks at amplifications and are certain subset of the genes? (07:29):So do you want to talk about how this panel offers some benefits over other large panels in the market? (08:46):Let's talk a little bit about how the results of this test can be used in patient care.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, hosts this episode of the "Answers From the Lab" podcast. He’s joined by Gianluca Pettiti, senior vice president and president of specialty diagnostics at Thermo Fisher Scientific to discuss their organizations’ collaboration and its value for patients.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss the future of laboratory medicine in a post-pandemic world.

(00:32):Before we get started, I'm really interested, could you give me a little bit of background on yourself and, uh, just where you work at Mayo Clinic? (01:31):So before we start talking about the tests, can you just tell me a little bit about TMA and in that disease state itself? (03:08):As we talk very specifically about this testing, so can you give me a brief overview of the assays we're using here at Mayo clinic to diagnose this disease state? (05:12):So this testing is really comprehensive and that it covers what you said, classic and alternative, correct? And that it's kind of making sure that anything that's outside of the norm, we're picking up in that one comprehensive test so you're not having to kind of pick through bits and pieces with a bunch of single individual tests. Am I correct and understand kind of how you brought that up? (08:39):As you get those results back, how does that affect how you treat a patient? What are the treatments for them as, as you go through this, once you've made that decision? (09:35):So there's a lot of movement in this space that is really probably driving the need for a lot of understanding this complement testing and seeing that full clinical picture, because you have to know you now have different therapies to choose from?

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., explain Mayo Clinic Laboratories, review its history, and describe how its work furthers Mayo Clinic’s mission.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., reflect on the dramatic advances that have taken place in laboratory medicine during the pandemic and what those changes might mean for the future.

(00:41) Before we get started talking about the panels, Dr. McKeon, could you provide a little background about yourself and your role here at Mayo Clinic? (01:23) I think it's important for our audience to know that you're both seeing patients and working in the lab, which helps us at Mayo Clinic to have a real understanding of what patients and physicians need to get an accurate diagnosis. Is that right?(02:09) I know there's a lot of panels that are impacted, Dr. McKeon. But could you give an overview, maybe talk about, in general, what changes are happening, so that our audience gets an understanding of what's going to change. (06:47) You said that the primary antibodies that are being removed are calcium channel, striations. You said an alpha three antibody. Are those the primary ones that we're removing from most panels, or did I miss a couple? (07:24) So our audience will be able to see on our website, a chart, which panels are going to include which of these antibodies, but it sounds like a couple are being removed entirely. And then a couple of the other ones — the alpha three, and of course PQ, and Lambert Eaton, and movement disorder — are going to stick around because they're specific to that phenotype, but they're being removed from the other panels. Correct? (08:29) Why did we decide to remove them now? And are you worried about anything in the future — the way our panels will be designed when these antibodies are removed? (11:27) So can you talk about ways that Mayo Clinic is partnering and available to help physicians pick the right test, to make sure that they're getting the antibodies needed and in the right context? (14:30) To wrap up Dr. McKeon, can you just share with our listeners what you're most excited about — or maybe the key takeaway for physicians that have used Mayo's testing and maybe are apprehensive about these changes, or maybe someone that hasn't ordered Mayo Clinic's testing before, but these changes could be an opening for them to utilize Mayo Clinic's resources. (15:39) Is there anything you want to add about antibodies on the horizon that will be added to our panels, Dr. McKeon?

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss the safety of COVID-19 vaccines in light of the recent pause in distribution of the Johnson & Johnson vaccine.

(00:55) Can you tell us what you've been working on since last May? (03:19) How many assays did you end up validating just for detection of that single virus? (04:36) How many specimens at the peak of the pandemic were you able to test in one day? (05:29) So can you tell us a little bit more about this test that you're using for sequencing? (08:18) How would a clinician who orders this test then use the results to change how they're caring for the patient? (10:22) So are there other tests like this on the market for actual clinical use? (11:18) We continue to learn more and more about COVID-19. We've now tackled identification and sequencing. What's next? (13:03) How have you been keeping yourself healthy and maintaining that healthy work-life balance? (13:53) Is there anything else you'd like to share with our listeners or viewers today?

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss vaccine passports. They review how proof of vaccination could be used along with other tools, like testing, to help curb the spread of COVID-19.

(00:34) I'm joined here today by Dr. Chris Klein. Sir, would you mind introducing yourself to our audience and telling them a little bit about your background? (1:19) I don't want this to be a review of the paper, sir, but could you just give maybe a recap of one or some of the key takeaways? (5:59) It was one of the first tests discovered, but we're not satisfied with the status quo and we continue to look for ways to make it better? (6:41) Can you just help the audience understand why that's necessary and why it's the best thing for patient care? (9:30) I think the role of MuSK is well understood, but it is a slight change in that it's going to automatically reflex. But the point of that is also to reduce turnaround time, right? (11:17) It sounds like it'd be hard to give a definitive diagnosis without the testing that we're offering right now, right? (13:13) What advice would you give for physicians or even laboratorians that might be trying to use our tests most efficiently? (17:00) What would you say Dr. Klein, to conclude, that you're most excited about regarding these changes that may have occurred?

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss the current rate of COVID-19 vaccination in the U.S. and address common questions about the vaccines.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., take a look at issues contributing to COVID-19 vaccine hesitancy. They address common myths surrounding the vaccines and discuss vaccine safety.

William Morice II, M.D., Ph.D., joins the "Answers From the Lab" podcast for his weekly leadership update. This week, Dr. Morice talks with Bobbi Pritt, M.D., about his career and the path he took to his current role as chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. March is Women's History Month, and in this episode, Dr. Morice and Bobbi Pritt, M.D., mark the occasion by discussing the legacy of female leaders at Mayo Clinic.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., consider how laboratory medicine will continue to evolve to meet health care needs beyond the COVID-19 pandemic.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss the changing face of laboratory medicine in the time of COVID-19.

(00:43) Could you please provide us with a little background on yourself, sir? (01:05) So Dr. McKeon, can you just give us a brief overview on what this test is? (02:18) And you mentioned the CRMP-5 antibody and recoverin antibody. Are those the only two antibodies involved in this particular evaluation? (02:43) So those two antibodies, are they both tested up front ? And then, if so, are there any reflexes in this evaluation? (03:25) What will the results look like when a physician orders this test? Will they just get a positive or negative, or are there a titer levels that are more significant? Can you help us? (04:24) This testing, like a lot of our autoimmune testing, is going to confirm that diagnosis based on the patient presentation that you described just a few minutes ago. Is that right, sir? (05:21) Do you have any other advice on when physicians should be ordering this test? (06:25) So what testing is currently available on the market? Maybe you can explain that, and how is ours different than what's currently available? (07:08) And why haven't we, sir? (07:40) I know recoverin is a brand new test for us. Is that also going to be available as a stand-alone where clients can order that? And then maybe, if so, could you elaborate on when that would be appropriate to order by itself? (08:45) Are there any other complementary tests that our audience should know about — maybe separate from autoimmune testing — that help to guide a diagnosis of paraneoplastic retinopathy or cancer-associated retinopathy? (09:58) I think that's really clear. But just to review, is the autoimmune testing ordered before those other tests, at the same time, or after?(10:29) I think a good place to end is how this testing is going to help patient care. Referring back to the struggles in this area with this patient population currently, and then how our test is going to be able to help direct a diagnosis or maybe prognosis and treatment. Can you talk about those things? (12:53) Are there any additional patient presentations that have been found with recoverin? (14:22) So if there are any questions about when to order this test or what to do with the results, they can really reach out to us anytime. Right, Dr. McKeon?

Matthew Binnicker, Ph.D., vice chair of practice for Mayo Clinic's Department of Laboratory Medicine and Pathology, joins William Morice II, M.D., Ph.D., president of Mayo Clinic Laboratories, for this week's "Answers From the Lab" leadership update. In this episode, Dr. Binnicker and Dr. Morice discuss the impact that emerging COVID-19 variants could have on virus testing, vaccine and spread.

(00:55) Dr. Murray, as we get started today, could you tell us a little bit more about yourself and your background here?(01:50) As you developed this assay, can you just give us a brief overview of it and how it works? (04:07) As you compare those two methods, what are some of the things that you're seeing that are the advantages of this new test?(07:02) When should patients really have this testing, and when are we performing it here at Mayo? (11:54) What do you think is one of the most interesting findings as you've gone through this whole process and work to develop and validate this testing? Which one really stands out to you more than anything?

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss the new nationwide strategy that the Biden administration is rolling out to combat COVID-19.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., tackle myths surrounding COVID vaccines and talk about where to find reliable vaccine information.

(00:50) Would you be able to tell us a little bit about yourself and your background? (01:26) So would you be able to provide us a brief overview of this assay? (02:16) When thinking about the application of this test, which patients should have this testing, and when should it be performed? (03:09) So after the test has been performed, how are the results used to guide patient care? (04:33) So what alternative testing options are available, and how might those compare to pancreatic elastase? (09:32) When you're meeting with a patient, and perhaps their parents or guardian, how do you typically explain why you're having this test? (10:47) Is there anything else you'd like to share with us today about this test?ResourcesPancreatic Elastase, Feces (Mayo Test ID: ELASF)Pancreatic Disease Testing

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss potential health care reform and other changes that could affect laboratory medicine in U.S. in the coming years.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss the new COVID-19 variants that are emerging and how those variants could have an impact on the pandemic going forward.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., look back at how the COVID-19 pandemic reshaped laboratory medicine throughout 2020.

(00:50) So maybe we'll just start with a simple question. If you could tell us a little bit about you and your background?(01:21) Let's go into, then, the dendritic cell enumeration test. What is this exactly? (03:46) What's innovative or different about this test? (04:56) What would you say is the primary use case of this test? (06:02) So how would you foresee this test being used? (08:06) So do you think that we'll be using this test for perhaps our very sick individuals here at Mayo Clinic? (08:37) So how would someone order this test? Is it available outside of Mayo Clinic, as well? (08:52) Is there anything else that you'd like to share about this whole process and coming up with this really novel test?

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., talk about the increased interest in health care professions, including those in laboratory medicine, that has been spurred on by the COVID-19 pandemic.

Tell us a little bit about your background and about yourself. Give us a brief overview of what are the previous approaches that have been used in the past for multiple myeloma testing. So can you take a moment and talk to me about the new approach and the new algorithm that your laboratory is working on implementing? So how does this new approach really benefit both hospitals across the country that we serve and the patients that they're trying to treat? What else is the lab working on when it comes to our multiple myeloma testing and our algorithms? Resources Plasma Cell Proliferative Disorder [A Test in Focus]Plasma Cell Proliferative Disorder, FISH, Bone Marrow (Mayo test ID: PCPDS)Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow (Mayo test ID: MSMRT)Chromosome Analysis, Hematologic Disorders, Bone Marrow (Mayo test ID: CHRBM)Mellors et al.: Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances. 2020;4(10): 2236-2244

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., debunk common face mask misconceptions in relation to the COVID-19 pandemic.

Anja Roden, M.D., a medical director for Mayo Clinic's Immunohistochemistry Laboratory, joins this episode of the "Answers From the Lab" podcast. Dr. Roden and Bobbi Pritt, M.D., discuss the development and evaluation of immunohistochemistry in situ hybridization and polymerase chain reaction for detection of SARS-CoV-2 in formalin-fixed paraffin-embedded tissues.

https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-research-confirms-critical-role-of-masks-in-preventing-covid-19-infection/

(00:48) Could you provide our listeners with a little bit about you and your background?(01:56) There's a fair amount of genetic hearing loss tests out there. Why did we decide to develop this one here at Mayo? (02:51) Can you tell me a little bit about the process that actually went into developing the test — the different research and that sort of thing? (04:03) What specific need do we meet with this particular test? (06:22) How were these results used in patient care? And what I mean by that is, when you're talking about the downstream management of the patient, what are some of the different treatments that can result from the use of this test? (08:16) How does our test compare to some of these tests that are out there right now?(09:48) Where in the patient's journey would this test be used? I know it's a diagnostic test and not a screening test, but could you expand on that a little more for me?

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss the latest on COVID-19 vaccines.

(01:07) Has the utility or the role of antibody testing changed or evolved in any way for you over the past months or since the pandemic began? (04:06) What do we know about the antibody response to the virus and how is our knowledge grown in that area? I think one question that people have is do we all make antibodies to the virus and how long do those antibodies last, and will they protect us from re-infection? (06:41) You mentioned briefly there's a neutralizing antibody test that recently received FDA emergency use authorization. Can you tell us a little bit about that and how you envision that test being used? (10:33) Can we reach herd immunity based on natural infection alone?(11:56) Once we have a vaccine, do you envision antibody testing being used to confirm that vaccination was successful? That people develop an antibody response because of the vaccine? (14:10) And would you say, out of all the antibody tests, how many of them are spike — that detect antibodies to the spike protein? It's all of them, right?ResourcesCOVID-19 Testing Resource CenterThe Importance of Antibody Testing in Addressing COVID-19COVID-19 TestingFrequently Asked Questions: COVID-19 Serology Testing

William Morice, II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., review the treatment options currently available for COVID-19.

(00:41) Dr. Bornhorst, could you provide our listeners with a little bit about you and your background? (01:15) Can you provide a brief overview of the alpha-gal galactose-alpha 1,3 galactose assay? (04:19) So I understand that most people obtain this allergy primarily from ticks and meat-derived products, and that it can cause symptoms such as hives, itching, difficulty breathing, and other unpleasant reactions. With that being said, can you tell us which patients should have this testing? (06:11) Do you know if there are other testing options available? (07:17) Can you share what factors determine which tests should be used and when?

William Morice, II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss herd immunity and COVID-19.

(00:47) Can you tell us a little bit about yourself and how your role has changed since COVID-19? (02:02) How do you feel that testing will help Mayo and hospitals respond to this coming season's challenge? (03:38) Can you tell us a little bit about the algorithm and how it helps to address perhaps potential resource shortages, knowing that we probably can't test everyone for everything all the time, and that may not be the best approach anyway? (05:50) In your mind, what significance does it have if there's a positive or a negative result from the different tests that we'll be doing in the algorithm for SARS-CoV-2, influenza and RSV? (08:18) But what about SARS-CoV-2 and influenza? Were you able to break that down at all for directing testing? (09:01) The symptoms for influenza and COVID-19 are so similar, would it be appropriate to say that any symptomatic patient you would recommend testing for both at the same time, but RSV testing would only be added on to that algorithm for the patients that are at specific risk for RSV disease, like our young kids and our immunocompromised folks? (09:51) So in using a triage system, would there be some patients that would go down the branches of the algorithm for testing versus those that wouldn't require testing? (10:21) So out of all of this, what lessons have you learned that other health care professionals would benefit from? (11:13) Have you seen anything inspiring that you've noticed during the pandemic? (12:29) Is there anything else that you'd like to share with our audience today?ResourcesCOVID-19 Testing Resource CenterCOVID-19 & influenza testing algorithm arms Mayo Clinic for the upcoming flu seasonExperts from Mayo Clinic featured in CAP Today

William Morice, II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., review the testing options currently available to detect COVID-19.

(00:45) Could you just provide our listeners with a little bit of information about you and your background? (01:00) The laboratory recently made some updates to this testing for minimal residual disease. Can you just give us a brief overview of that assay? (03:22) So these patients go through these treatments, and at what point do they really need this testing, or when should it be considered by clinicians to perform it? (05:18) What brought the laboratory to flow cytometry for this MRD test for this particular disease state? Why did we not choose those other methods? (09:44) So hearing you talk about how this test is serving the entire patient population, how are these results for this minimal residual disease test used for patient care?

Resources:https://www.cdc.gov/coronavirus/2019-ncov/community/large-events/considerations-for-events-gatherings.html

Speaker 1: (00:39) Can you start by sharing a little bit about yourself and your expertise for our listeners? Speaker 1: (01:12) We're in this pandemic with COVID-19, and I'm hearing about people having hematologic responses to COVID-19. Can you tell us a little bit about what these responses are? Speaker 2: (04:53) Here at Mayo Clinic, do we have an assay or a testing profile that could assist physicians who are dealing with COVID-19 and their patients and help them look at how their patients are doing? Speaker 2: (07:09) Why is this testing important and would it affect COVID-19 patient management? Speaker 2: (08:49) What challenges have you encountered during this pandemic and how have you overcome them? Speaker 2: (10:04) Is there anything you've seen that you found has been particularly inspiring during the pandemic? Speaker 2: (12:18) Is there anything else that you'd like to share with our audience?

William Morice, II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. With a surge in new cases happening now, and flu season coming soon, Dr. Morice and Bobbi Pritt, M.D., discuss the importance of continuing to follow safety precautions to help prevent COVID-19.

Speaker 1: (01:20) Today we want to talk about the MDM2 gene amplification assay. Can you give us a little bit of an overview of that test? Speaker 1: (02:16) Is there a certain subset of patients that should have this testing, and when should it be performed on those patients? Speaker 1: (02:50) So for those patients then, are there any other alternative test options that are available for them, or how else might these patients be diagnosed, and how does this specific task compare with the other options out there? Speaker 1: (03:59) It sounds like this test is going to be used primarily for a diagnosis in this specific case. Then how does that impact patient care? Speaker 1: (04:50) Can you explain this in a way that a patient would understand why this test would be done? Resources MDM2 (12q15) Amplification, Well-Differentiated Liposarcoma/Atypical Lipomatous Tumor, FISH, Tissue

Full Show Notes:Speaker 1: (00:49) Can you share a little bit about yourself and how your role has changed since COVID-19 started? Speaker 1: (01:52) What kind of shortages have you seen in our laboratories? And maybe you could tell us a little bit about some innovative solutions your team's been working on to combat those shortages. Speaker 1: (04:41) Have you seen shortages in other areas of testing besides COVID testing? Speaker 1: (07:35) Are there any lessons you've learned from this whole pandemic that other laboratory professionals would benefit from hearing about? Speaker 1: (09:06) Has there been anything inspiring throughout this pandemic that you've noticed that you'd like to share with our listeners? Speaker 1: (10:14) Is there anything else that you'd like to share with our audience today?

William Morice, II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., explain the difference between collecting a specimen sample at home to be used for COVID-19 testing versus performing a COVID-19 test at home. They also discuss factors that can affect test results and how to ensure accurate testing.

Resources:https://pubmed.ncbi.nlm.nih.gov/25502528/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538476/